HaematologyMultiple Myeloma

Multiple Myeloma: On the Threshold of Cure

Four bispecific antibodies, two CAR-T therapies, and a treatment landscape that moves monthly

SR-2026-006

EditorMara Voss

CopywritersEditorial Team

Coming Soon

Multiple Myeloma: On the Threshold of Cure

Four bispecific antibodies, two CAR-T therapies, and a treatment landscape that moves monthly

Why We Are Covering This

Multiple myeloma now has four approved bispecific antibodies and expanding CAR-T indications, but no standardized sequencing framework. Experienced hematologists are choosing between agents without clear evidence-based guidance.

What to Expect

You will leave with a decision framework for sequencing CAR-T versus bispecifics, an understanding of target selection across BCMA, GPRC5D, and FcRH5, and clarity on what the emerging cure-rate data means for long-term management.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first

thelifesciencefeed.com · Special Report

SR-2026-00607/26

Lymphoma

Liso-Cel Delivers Durable OS Benefit in R/R LBCL, Redefining Treatment

Lisocabtagene maraleucel (liso-cel) significantly extended overall survival in relapsed/refractory large B-cell lymphoma, establishing a new benchmark for second-line therapy.

Immune Thrombocytopenia

Monoclonal Antibodies May Complicate Transfusion Testing

Monoclonal antibodies, particularly IgG4 anti-CD47, may induce erythrophagocytosis and interfere with transfusion compatibility testing, posing a challenge for patient management.

Sickle Cell Disease

Blood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections

Modern blood transfusion practices, including pathogen inactivation, have significantly reduced the risk of transfusion-transmitted infections, improving patient safety.

Leukemia

EHA 2026

Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)

Chemotherapy-free regimens for pediatric acute promyelocytic leukemia (APL) demonstrate superior efficacy and reduced toxicity compared to traditional chemotherapy.

Multiple Myeloma: On the Threshold of Cure

Multiple Myeloma: On the Threshold of Cure

Be first when this report publishes

Related Articles